Abstract
Objective
As the gut microbiota has attracted considerable attention in recent years, the aim of the present study is introducing a new microbiota research group at Endocrinology and Metabolism Research Institute (EMRI) that collaborates with national and international research centers for microbiome research projects management.
Methods
All the documents from EMRI focused on the microbiota field were collected using PubMed, Scopus, and Web of Science electronic databases from the inception up to June 2020.
Results
Findings of the EMRI research projects on the microbiota field were reviewed in this study and we highlighted some specific primary results of gut microbiota composition in the Iranian population. Moreover, applications of the developed Microbiota Database are introduced.
Conclusion
Enhancement of investment in this field and interdisciplinary collaborations are needed to progress our knowledge about the Iranian gut microbiota composition and develop microbiota modulating interventions over the next decade.
Similar content being viewed by others
Data availability
Not applicable.
References
Ejtahed HS, Soroush AR, Angoorani P, Larijani B, Hasani-Ranjbar S. Gut microbiota as a target in the pathogenesis of metabolic disorders: a new approach to novel therapeutic agents. Horm Metab Res. 2016;48(6):349–58.
NHMPA Team. A review of 10 years of human microbiome research activities at the US National Institutes of Health, fiscal years 2007-2016. Microbiome. 2019;7(1):31.
Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss JA, et al. The NIH human microbiome project. Genome Res. 2009;19(12):2317–23.
Gupta VK, Paul S, Dutta C. Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity. Front Microbiol. 2017;8:1162.
Aazami H, DehghanBanadaki H, Ejtahed HS, Fahimfar N, Razi F, Pasalar P, et al. The landscape of microbiota research in Iran; a bibliometric and network analysis. J Diabetes Metab Disord. 2020;19(1):163–77.
Ejtahed HS, Tabatabaei-Malazy O, Soroush AR, Hasani-Ranjbar S, Siadat SD, Raes J, et al. Worldwide trends in scientific publications on association of gut microbiota with obesity. Iranian J Basic Medic Sci. 2019;22(1):65–71.
Ejtahed HS, Angoorani P, Soroush AR, Hasani-Ranjbar S, Siadat S, Larijani B. Gut microbiota-derived metabolites in obesity: a systematic review. Biosci Microbiota Food Health. 2020. https://doi.org/10.12938/bmfh.2019-026.
Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015;5:8096.
Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513(7516):59–64.
Ejtahed HS, Hasani-Ranjbar S, Larijani B. Human microbiome as an approach to personalized medicine. Altern Ther Health Med. 2017;23(6):8–9.
Ejtahed HS, Soroush AR, Siadat SD, Hoseini-Tavassol Z, Larijani B, Hasani-Ranjbar S. Targeting obesity management through gut microbiota modulation by herbal products: a systematic review. Complement Ther Med. 2019;42:184–204.
Ejtahed HS, Angoorani P, Hasani-Ranjbar S, Siadat SD, Ghasemi N, Larijani B, et al. Adaptation of human gut microbiota to bariatric surgeries in morbidly obese patients: a systematic review. Microb Pathog. 2018;116:13–21.
Tabasi M, Ashrafian F, Khezerloo JK, Eshghjoo S, Behrouzi A, Javadinia SA, et al. Changes in gut microbiota and hormones after bariatric surgery: a bench-to-bedside review. Obes Surg. 2019;29(5):1663–74.
Ejtahed H-S, Angoorani P, Soroush A-R, Atlasi R, Hasani-Ranjbar S, Mortazavian AM, et al. Probiotics supplementation for the obesity management; a systematic review of animal studies and clinical trials. J Funct Foods. 2019;52:228–42.
Ejtahed HS, Hasani-Ranjbar S. Neuromodulatory effect of microbiome on gut-brain axis; new target for obesity drugs. J Diabetes Metab Disord. 2019;18(1):263–5.
Ardeshirlarijani E, Tabatabaei-Malazy O, Mohseni S, Qorbani M, Larijani B, Jalili RB. Effect of probiotics supplementation on glucose and oxidative stress in type 2 diabetes mellitus: A meta-analysis of randomized trials. DARU J Pharm Sci. 2019;5:1–1.
Homayouni-Rad A, Soroush AR, Khalili L, Norouzi-Panahi L, Kasaie Z, Ejtahed HS. Diabetes management by probiotics: current knowledge and future Pespective. Int J Vitam Nutr Res. 2016;86(3–4):215–27.
Rad AH, Abbasalizadeh S, Vazifekhah S, Abbasalizadeh F, Hassanalilou T, Bastani P, et al. The future of diabetes management by healthy probiotic microorganisms. Curr Diabetes Rev. 2017;13(6):582–9.
Razmpoosh E, Javadi A, Ejtahed HS, Mirmiran P, Javadi M, Yousefinejad A. The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: a randomized placebo controlled trial. Diabetes Metab Syndr. 2019;13(1):175–82.
Razmpoosh E, Javadi M, Ejtahed HS, Mirmiran P. Probiotics as beneficial agents in the management of diabetes mellitus: a systematic review. Diabetes Metab Res Rev. 2016;32(2):143–68.
Ejtahed HS, Tabatabaei-Malazy O, Hoseini-Tavassol Z, Hasani-Ranjbar S, Soroush AR, Larijani B. Effect of probiotic foods and supplements on blood pressure: a systematic review of meta-analyses studies of controlled trials. J Diabetes Metab Disord. 2020;19(1):617–23.
Milajerdi A, Mousavi SM, Sadeghi A, Salari-Moghaddam A, Parohan M, Larijani B, Esmaillzadeh A. The effect of probiotics on inflammatory biomarkers: a meta-analysis of randomized clinical trials. Eur J Nutri. 2020;59(2):633–49
Zamani B, Sheikhi A, Namazi N, Larijani B, Azadbakht L. The effects of supplementation with probiotic on biomarkers of oxidative stress in adult subjects: A systematic review and meta-analysis of randomized trials. Probio Antimicrob Proteins. 2019;21:1–0
Ejtahed HS, Tito RY, Siadat SD, Hasani-Ranjbar S, Hoseini-Tavassol Z, Rymenans L, et al. Metformin induces weight loss associated with gut microbiota alteration in non-diabetic obese women: a randomized double-blind clinical trial. Eur J Endocrinol. 2018;180(3):165–76.
Ejtahed HS, Hoseini-Tavassol Z, Khatami S, Zangeneh M, Behrouzi A, Ahmadi Badi S, et al. Main gut bacterial composition differs between patients with type 1 and type 2 diabetes and non-diabetic adults. J Diabetes Metab Disord. 2020;19(1):265–71.
Ejtahed HS, Angorani P, Soroush AR, Siadat SD, Shirzad N, Hasani-Ranjbar S, et al. Our little friends with big roles: alterations of the gut microbiota in thyroid disorders. Endocr Metab Immune Disord Drug Targets. 2020;20(3):344–50.
Author information
Authors and Affiliations
Contributions
HSE, SDS and BL designed the study. HSE, SHR and SDS drafted the manuscript. ARS helped in interpretation of data. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ejtahed, HS., Hasani-Ranjbar, S., Soroush, AR. et al. Microbiota research in Iran; current knowledge and future perspective. J Diabetes Metab Disord (2021). https://doi.org/10.1007/s40200-020-00703-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s40200-020-00703-0